CLLSA at NICE and preliminary NICE guidance for two new CLL treatments
The CLLSA regulatory appraisals volunteer group are participating in six NICE consultations. CLLSA representatives commented on the following NICE documents and attended the Scope, Appraisal workshops and participated on appraisal committees to date this year this has resulted in the excellent news that two new treatments have already received preliminary recommendation by NICE for NHS treatment of CLL in England and Wales:
04 November 2014 Ofatumumab in combination with Chlorambucil for previously untreated chronic lymphocytic leukaemia gained provisional preliminary NICE approval and guidance.
Ofatumumab plus chlorambucil is recommended as a cost-effective use of NHS resources for untreated chronic lymphocytic leukaemia in people who are ineligible For fludarabine-based therapy, only if bendamustine is not suitable and the company provides ofatumumab with the discount agreed in the patient access scheme.
Read the full NICE press release: https://www.nice.org.uk/news/press-and-media/niceproposes-to-recommend-a...
02 December 2014 Obinutuzumab in combination with Chlorambucil for previously untreated chronic lymphocytic leukaemia gained provisional preliminary NICE approval and guidance
Obinutuzumab, in combination with chlorambucil, is recommended as an option for adults with untreated chronic lymphocytic leukaemia who have co morbidities that make fulldose fludarabine-based therapy unsuitable for them, only if: bendamustine-based therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme.
Read the full NICE press release and guidance Here